Avanos Medical (NYSE:AVNS) Issues FY24 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its FY24 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of $1.30-1.45 for the period, compared to the consensus estimate of $1.38. The company issued revenue guidance of $685-705 million, compared to the consensus revenue estimate of $691.07 million.

Avanos Medical Price Performance

AVNS stock traded down $0.03 during trading on Friday, hitting $19.68. The company had a trading volume of 246,254 shares, compared to its average volume of 211,695. The company has a fifty day moving average price of $19.19 and a two-hundred day moving average price of $19.91. Avanos Medical has a fifty-two week low of $17.24 and a fifty-two week high of $26.56. The company has a debt-to-equity ratio of 0.14, a current ratio of 2.28 and a quick ratio of 1.38.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Tuesday, February 20th. The company reported $0.36 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.01). Avanos Medical had a positive return on equity of 3.98% and a negative net margin of 9.15%. The firm had revenue of $173.30 million for the quarter, compared to analyst estimates of $170.43 million. During the same quarter last year, the business earned $0.60 EPS. The company’s revenue for the quarter was down 4.6% compared to the same quarter last year. On average, analysts expect that Avanos Medical will post 1.38 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com cut Avanos Medical from a buy rating to a hold rating in a report on Friday.

Insider Buying and Selling at Avanos Medical

In related news, CFO Michael Greiner sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $19.12, for a total value of $152,960.00. Following the completion of the transaction, the chief financial officer now owns 151,495 shares in the company, valued at approximately $2,896,584.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 2.90% of the company’s stock.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.